Compare Divis Laboratories with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs TORRENT PHARMA - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES TORRENT PHARMA DIVIS LABORATORIES/
TORRENT PHARMA
 
P/E (TTM) x 52.0 36.0 144.2% View Chart
P/BV x 12.0 9.1 131.3% View Chart
Dividend Yield % 0.5 0.7 76.4%  

Financials

 DIVIS LABORATORIES   TORRENT PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
TORRENT PHARMA
Mar-19
DIVIS LABORATORIES/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,6391,964 83.5%   
Low Rs1,1151,245 89.6%   
Sales per share (Unadj.) Rs186.3453.4 41.1%  
Earnings per share (Unadj.) Rs51.025.8 197.6%  
Cash flow per share (Unadj.) Rs57.362.3 92.0%  
Dividends per share (Unadj.) Rs16.0017.00 94.1%  
Dividend yield (eoy) %1.21.1 109.7%  
Book value per share (Unadj.) Rs261.8279.2 93.8%  
Shares outstanding (eoy) m265.47169.22 156.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.43.5 208.9%   
Avg P/E ratio x27.062.2 43.4%  
P/CF ratio (eoy) x24.025.8 93.3%  
Price / Book Value ratio x5.35.7 91.5%  
Dividend payout %31.465.9 47.6%   
Avg Mkt Cap Rs m365,592271,513 134.6%   
No. of employees `00011.813.6 87.1%   
Total wages/salary Rs m5,42314,038 38.6%   
Avg. sales/employee Rs Th4,175.15,642.6 74.0%   
Avg. wages/employee Rs Th457.71,032.4 44.3%   
Avg. net profit/employee Rs Th1,141.8320.9 355.9%   
INCOME DATA
Net Sales Rs m49,46376,728 64.5%  
Other income Rs m1,556571 272.8%   
Total revenues Rs m51,01977,299 66.0%   
Gross profit Rs m18,71819,831 94.4%  
Depreciation Rs m1,6896,177 27.3%   
Interest Rs m355,038 0.7%   
Profit before tax Rs m18,5519,187 201.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,570 0.0%   
Tax Rs m5,0231,254 400.7%   
Profit after tax Rs m13,5274,363 310.0%  
Gross profit margin %37.825.8 146.4%  
Effective tax rate %27.113.6 198.5%   
Net profit margin %27.35.7 480.9%  
BALANCE SHEET DATA
Current assets Rs m46,50150,375 92.3%   
Current liabilities Rs m8,46851,653 16.4%   
Net working cap to sales %76.9-1.7 -4,617.2%  
Current ratio x5.51.0 563.1%  
Inventory Days Days13192 142.1%  
Debtors Days Days8668 125.7%  
Net fixed assets Rs m25,79783,648 30.8%   
Share capital Rs m531846 62.7%   
"Free" reserves Rs m68,96246,397 148.6%   
Net worth Rs m69,49347,244 147.1%   
Long term debt Rs m039,129 0.0%   
Total assets Rs m80,383141,209 56.9%  
Interest coverage x531.02.8 18,806.1%   
Debt to equity ratio x00.8 0.0%  
Sales to assets ratio x0.60.5 113.2%   
Return on assets %16.96.7 253.4%  
Return on equity %19.59.2 210.8%  
Return on capital %26.712.3 216.8%  
Exports to sales %00-   
Imports to sales %24.60-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,23822,103 186.6%   
Fx outflow Rs m12,4055,522 224.7%   
Net fx Rs m28,83316,581 173.9%   
CASH FLOW
From Operations Rs m9,54317,981 53.1%  
From Investments Rs m-6,854-2,413 284.1%  
From Financial Activity Rs m-2,459-13,145 18.7%  
Net Cashflow Rs m2302,380 9.6%  

Share Holding

Indian Promoters % 52.0 71.5 72.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 7.0 168.1%  
FIIs % 19.0 12.6 150.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 8.8 195.5%  
Shareholders   31,796 26,511 119.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   DISHMAN PHARMA  CADILA HEALTHCARE  SUVEN LIFESCIENCES  DR. DATSONS LABS  GLENMARK PHARMA  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex Crashed 600 Points Today(Closing)

Indian share markets witnessed a sharp sell-off today and ended their session deep in the red.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

My View on ITC(Fast Profits Daily)

Oct 23, 2020

What do the charts say about ITC?

Why ITC and not HUL is my Idea of a Good Investment Right Now(Views On News)

Oct 15, 2020

Rahul Shah discusses HUL's lost decade and its implications for ITC.

PSU Banks Will Move Up Again(Profit Hunter)

Oct 27, 2020

My charts tell me PSU banks are set for a rebound.

Why India's Drone Revolution is a 4x Profit Opportunity(Profit Hunter)

Oct 16, 2020

My research on India's leading defence companies brought me to one major player in drone manufacturing.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Oct 28, 2020 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS